AAFP pact with Coke distasteful to some

Share this article:
Drink responsibly: Coca-Cola Co. is sponsoring advice on an AAFP consumer website
Drink responsibly: Coca-Cola Co. is sponsoring advice on an AAFP consumer website
An alliance with the nation's largest soft drink maker to sponsor advice on sugar-free alternatives has spurred criticism of the American Academy of Family Physicians (AAFP).

The unlikely union kicked off last month, with the big professional society saying it will use the Coca-Cola Co.'s six-figure grant to provide recommendations to consumers on FamilyDoctor.org, the society's consumer portal.

“There have been articles about sugary beverages and sweeteners in many journals, such as Journal of the American Medical Association, The New England Journal of Medicine and American Journal of Clinical Nutrition over the last five, six years,” Dr. Douglas Henley, EVP and CEO of the academy, told MM&M. “It's that type of information we will be pointing to.”

But AAFP has taken heat for forging the one-year pact, the first agreement in its new Consumer Alliance program, which is designed to diversify the academy's funding sources beyond the pharmaceutical industry.  

A group of health advocates protested that the Coke deal will bias the academy's recommendations, writing, “it would be naïve to think that the AAFP would risk offending its funder.” Yesterday the Associated Press even suggested that some of the society's members are quitting over the affiliation with Coke.

AAFP contends that it will post only fact-based content addressing sugar-free alternatives to help patients make healthy choices. It intends to begin posting the information in early 2010.

Henley said the academy is in discussions with several other potential corporate sponsors and that Coke “was first out of the chute in terms of signing a contract.”

He likened the sponsorship to an unrestricted educational grant: “That's why you build the firewalls, to prevent bias from entering into the equation,” he said.

Nevertheless, he said, the feedback has heightened sensitivity to providing only evidence-based information.

“The concerns expressed simply reflect the seriousness by which we take our historical position about editorial independence relative to content development,” said Henley. “We hope people will hold us accountable for the content and simply not rush to judgment.”
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...